Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study
Antonio Sisinni, Luca Rossi, Antonio Battista, Enrico Poletti, Federica Battista, Rosa Alessia Battista, Alessandro Malagoli, Andrea Biagi, Alessia Zanni, Concetta Sticozzi, Greta Comastri, Massimiliano M Marrocco-Trischitta, Alberto Monello, Alberto Margonato, Francesco Bandera, Pasquale Vergara, Marco Guazzi, MD Cosmo Godino
International Journal of Cardiology, doi:10.1016/j.ijcard.2021.09.058
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
b Values are avaible for 97% of the entire study cohort. c Fever was classified as highest patient temperature 37.3 °C or higher. To minimize interference of treatment, the highest patient temperature was defined using the self-reported highest temperature before taking antipyretic drug. d ACE-I/ARB use was defined as use of these drugs at the time of admission that continued through hospitalization. e Values are avaible for 25% of the entire study cohort. f Including azithromycin 500 mg daily dose p.o. and/or ceftriaxone 2000 mg daily dose i.v.
J o u r n a l P r e -p r o o f Journal Pre-proof J o u r n a l P r e -p r o o f
References
Ackermann, Verleden, Kuehnel, Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2015432Asia, Mediterranean, Pacific, COVID-19 Weekly Epidemiological Update
Bianconi, Violi, Fallarino, Pignatelli, Sahebkar et al., Is Acetylsalicylic Acid a Safe and P i Ch i A P i wi h CO D -19 ?, Drugs,
doi:10.1007/s40265-020-01365-1Bikdeli, Madhavan, Jimenez, COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Followup, J Am Coll Cardiol,
doi:10.1016/j.jacc.2020.04.031Bilaloglu, Aphinyanaphongs, Jones, Iturrate, Hochman et al., Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System, JAMA,
doi:10.1001/jama.2020.13372Chaudhary, Kreutz, Bliden, Gurbel, Personalizing Antithrombotic Therapy in COVID-19 : Th b g h nd Thromboelastometry
Chiarito, Sanz-Sánchez, Cannata, Monotherapy with a P2Y 12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis, Lancet,
doi:10.1016/S0140-6736(20)30315-9Chow, Khanna, Kethireddy, Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19, Anesth Analg
Ciceri, Beretta, Scandroglio, Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis, Crit Care Resusc
Eikelboom, Hirsh, Spencer, Baglin, Weitz, Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest,
doi:10.1378/chest.11-2293Fox, Akmatbekov, Harbert, Li, Brown et al., Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans, Lancet Respir Med,
doi:10.1016/S2213-2600(20)30243-5Ganatra, Hammond, Nohria, The Novel Coronavirus Disease (COVID-19) Threat for Patients With Cardiovascular Disease and Cancer, JACC CardioOncology,
doi:10.1016/j.jaccao.2020.03.001Gu, Tyagi, Jain, Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation, Nat Rev Cardiol,
doi:10.1038/s41569-020-00469-1Gurbel, Bliden, Butler, Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease The ONSET / OFFSET Study,
doi:10.1161/CIRCULATIONAHA.109.912550Gurbel, Bliden, Rout, Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population, J Thromb Thrombolysis,
doi:10.1007/s11239-021-02435-1J O U R N A L P R E, -p r o o f
J O U R N A L P R E, -p r o o f Journal Pre-proof
J O U R N A L P R E, -p r o o f Journal Pre-proof
Lemos, Do, Santo, Salvetti, Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)
Nishiga, Wang, Han, Lewis, Wu, COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives, Nat Rev Cardiol,
doi:10.1038/s41569-020-0413-9Organization, When COVID-19 Disease Is Suspected: Interim Guidance
Ouyang, Wang, Liu, Ma, Ding, Effects of antiplatelet therapy on the mortality rate of patients with sepsis: A meta-analysis, J Crit Care,
doi:10.1016/j.jcrc.2018.12.004Panka, De Grooth, Spoelstra-De Man, Looney, Tuinman, Prevention or Treatment of Ards With Aspirin: A Review of Preclinical Models and Meta-Analysis of Clinical Studies, Shock,
doi:10.1097/SHK.0000000000000745Paranjpe, Fuster, Lala, Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19, J Am Coll Cardiol,
doi:10.1016/j.jacc.2020The, Activ-4a, Investigators, Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2105911
